Navigating The CRISPR Patent Landscape and Understanding The FDA and its Process

“What can be a better day to talk about the complex CRISPR/Cas9 patent landscape than the big day that the Nobel Prize was awarded to pioneers of this revolutionary technology? The story of the continuing dispute on the fundamental CRISPR/Cas9 patents offers a lot of insights for IP stake holders in highly competitive and valuable fields of technology,” patent associate Dr. Yan Qi noted, our first speaker in the fourth class of our Patent Law Course offered by Morrison & Foerster and GSAS Harvard Biotech Club. MoFo partner and head of our FDA Regulatory + Life Sciences Compliance practice Bethany Hills followed with an FDA Primer on the agency’s drug and software approval process and expressed that “It was so much fun to field so many insightful questions about really nuanced FDA issues and product types and I hope the attendees now appreciate the complex interaction between patent, foundational science and the FDA regulatory pathways.”

Next week’s class will be taught by firmwide co-chair of the Emerging Companies & Venture Capital Group, chair of MoFo’s San Diego Corporate Group, and managing partner of the San Diego office  Steve Rowles, who will provide the Top 10 Things to Know About When Forming a Life Sciences Startup. Matt Karlyn, partner in MoFo’s Commercial Life Sciences Transactions + Licensing Group and in the firm’s Technology Transactions practice, will discuss patent licenses, including a discussion of University Technology Transfer.